nm23-H1 Expression in non-Hodgkin and Hodgkin Lymphomas

We assessed for nm23-H1 expression in 262 lymphoid neoplasms including 191 B-cell non-Hodgkin lymphoma (NHL), 54 T-cell NHL, and 17 Hodgkin lymphoma (HL). We used a monoclonal anti-nm23-H1 antibody, routinely processed tissue, and immunohistochemical methods. We semiquantified the percentage of positive cells (0%, <25%, 25% to 75%, and >75%) and also estimated staining intensity (1 to 3+). Some percentage of nm23-H1 positive cells was detected in almost all types of NHL and HL, but T-cell NHL (87%) and HL (94.1%) more frequently had >75% positive cells than B-cell NHL (47.6%) (T- NHL vs. B-NHL, P<0.0001; HL vs. B-NHL, P=0.0011). High-intensity (3+) nm23-H1 staining was also more frequently observed in T-cell NHL (61.1%) and HL (76.5%) compared with B-cell NHL (43.5%) (T- NHL vs. B-NHL, P=0.013; HL vs. B-NHL, P=0.007). In most types of NHL and HL the nm23-H1 immunoreactivity was predominantly cytoplasmic. However, in plasma cell myeloma (PCM) nm23-H1 immunoreactivity was predominantly nuclear. In B-cell NHL, the percentage of nm23-H1–positive cells and the intensity of staining was not significantly different between various lymphoma types with the exception of PCM. We conclude that nm23-H1 is expressed in most types of B-cell and T-cell NHLs and HL, with a greater number of positive cells and higher staining intensity in T-cell NHL and HL, and PCM often being negative. The abundant intracellular expression of nm23-H1 suggests that serum levels of nm23-H1 are a reflection of tumor content. Unlike the conclusions of earlier studies, nm23-H1 expression in B-cell NHL was not significantly increased in clinically aggressive versus indolent neoplasms.

[1]  Ju-Han Lee,et al.  nm23-H1 Protein Expression and Gene Mutation in 150 Patients with Non-Hodgkin's Lymphomas , 2006, Journal of Korean medical science.

[2]  R. Versteeg,et al.  Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene encodes a novel protein, NM23-LV. , 2006, Genomics.

[3]  C. Welter,et al.  Expression of the nm23 homologues nm23‐H4, nm23‐H6, and nm23‐H7 in human gastric and colon cancer , 2005, The Journal of pathology.

[4]  J. de Gunzburg,et al.  Subcellular localization of A and B Nm23/NDPK subunits. , 2004, Experimental cell research.

[5]  H. Nakamine,et al.  Clinical Significance of Intracytoplasmic nm23-H1 Expression in Diffuse Large B-Cell Lymphoma , 2004, Clinical Cancer Research.

[6]  J. Okabe‐Kado,et al.  Physiological and Pathological Relevance of Extracellular NM23/NDP Kinases , 2003, Journal of bioenergetics and biomembranes.

[7]  T. McDonnell,et al.  Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. , 2002, American Journal of Clinical Pathology.

[8]  A. Kowluru,et al.  Localization and characterization of the mitochondrial isoform of the nucleoside diphosphate kinase in the pancreatic beta cell: evidence for its complexation with mitochondrial succinyl-CoA synthetase. , 2002, Archives of biochemistry and biophysics.

[9]  J. Okabe‐Kado.  Serum nm23-H1 Protein as a Prognostic Factor in Hematological Malignancies , 2002, Leukemia & lymphoma.

[10]  T. McDonnell,et al.  Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. , 2001, The American journal of pathology.

[11]  B. Dörken,et al.  Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. , 2001, Blood.

[12]  Y. Honma,et al.  Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma , 2001, Leukemia.

[13]  Y. Honma,et al.  Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. , 2001, Blood.

[14]  B. Calabretta,et al.  Neuroblastoma specific effects of DR-nm23 and its mutant forms on differentiation and apoptosis , 2000, Cell Death and Differentiation.

[15]  Y. Honma,et al.  Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia. , 2000, Blood.

[16]  P. Steeg,et al.  Nm23/Nucleoside Diphosphate Kinase in Human Cancers , 2000, Journal of bioenergetics and biomembranes.

[17]  D. Lambeth,et al.  The Human Nm23/Nucleoside Diphosphate Kinases , 2000, Journal of bioenergetics and biomembranes.

[18]  J. Janin,et al.  The Human nm23-H4 Gene Product Is a Mitochondrial Nucleoside Diphosphate Kinase* , 2000, The Journal of Biological Chemistry.

[19]  S. Pals,et al.  Cell adhesion receptors in lymphoma dissemination. , 2000, Blood.

[20]  Y. Honma,et al.  Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. , 1999, Blood.

[21]  H. Lee,et al.  Inhibitory activity of nm23-H1 on invasion and colonization of human prostate carcinoma cells is not mediated by its NDP kinase activity. , 1999, Cancer letters.

[22]  H. Snoeck,et al.  Decrease in Nucleoside Diphosphate Kinase (NDPK/nm23) Expression during Hematopoietic Maturation* , 1998, The Journal of Biological Chemistry.

[23]  S. Tomoyasu,et al.  Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies. , 1998, Blood.

[24]  I. Lascu,et al.  nm23-H4, a new member of the family of human nm23/nucleoside diphosphate kinase genes localised on chromosome 16p13 , 1997, Human Genetics.

[25]  H. Kovar,et al.  Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness. , 1996, British Journal of Cancer.

[26]  B. Dörken,et al.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. , 1996, Blood.

[27]  B Calabretta,et al.  Overexpression of DR-nm23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32Dc13 myeloid cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Steeg,et al.  Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. , 1993, Oncogene.

[29]  D. Stram,et al.  Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. , 1993, Oncogene.

[30]  E. Roos.  Adhesion molecules in lymphoma metastasis , 1991, Cancer and Metastasis Reviews.

[31]  J E Talmadge,et al.  Evidence for a novel gene associated with low tumor metastatic potential. , 1988, Journal of the National Cancer Institute.

[32]  Y. Honma,et al.  Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma , 2003, Leukemia.

[33]  Y. Honma,et al.  Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia. , 1998, Leukemia & lymphoma.

[34]  P. Steeg,et al.  Identification and characterization of the promoter for the human metastasis suppressor gene nm23-H1. , 1996, Archives of medical research.